Evaluating CART-EGFR-IL13Ra2 Cells Following Lymphodepleting Chemotherapy in Patients With EGFR-Amplified Recurrent Glioblastoma

Age
99 years or below
Gender
All
participants needed
50
Location
1

Brief description of study

This research study is being conducted to evaluate an experimental drug called CART EGFR-IL13Ra2 cells in patients with glioblastoma that has returned or worsened on current treatment.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Lymphodepleting Chemotherapy,Glioblastoma
  • Age: 99 years or below
  • Gender: All
Updated on 04 Aug 2024. Study ID: 850297
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Office of Clinical Research